1776 Wealth LLC lessened its position in Danaher Co. (NYSE:DHR – Free Report) by 5.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,723 shares of the conglomerate’s stock after selling 104 shares during the period. 1776 Wealth LLC’s holdings in Danaher were worth $479,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter valued at $25,000. nVerses Capital LLC bought a new stake in shares of Danaher during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Danaher during the 2nd quarter worth about $51,000. Financial Connections Group Inc. bought a new stake in shares of Danaher during the 2nd quarter worth about $51,000. Finally, Western Pacific Wealth Management LP bought a new stake in shares of Danaher during the 1st quarter worth about $55,000. Institutional investors own 79.05% of the company’s stock.
Insider Buying and Selling
In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.10% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on DHR
Danaher Stock Down 3.7 %
Shares of NYSE DHR traded down $8.88 during mid-day trading on Friday, hitting $230.50. The company had a trading volume of 5,435,775 shares, compared to its average volume of 2,760,084. Danaher Co. has a one year low of $206.30 and a one year high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $166.49 billion, a PE ratio of 43.99, a price-to-earnings-growth ratio of 4.44 and a beta of 0.85. The firm has a 50-day simple moving average of $262.20 and a two-hundred day simple moving average of $260.38.
Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the company posted $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities analysts expect that Danaher Co. will post 7.51 EPS for the current year.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- What Investors Need to Know to Beat the Market
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Industrial Products Stocks Investing
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Basic Materials Stocks Investing
- Time to Load Up on Home Builders?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.